Ongoing
Determinants of Increased Risk of Cardiovascular Diseases in Individuals Living with HIV
Learn MoreCompleted
Prospective investigation of the relationship between food insecurity and health and behavioural outcomes in HIV-HCV co-Infection: Clues for prevention interventions. A food security & HIV-HCV sub-study of the Canadian Co-Infection Cohort (CTN 222)
Learn MoreCompleted
A multicenter randomized, double-blind, controlled study of NGX-4010 for the treatment of painful HIV-associated neuropathy: Trial results
Learn MoreCompleted
Trial of Citalopram for the Prevention of Depression
Learn MoreCompleted
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
Learn MoreCompleted
A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results
Learn MoreCompleted
A Phase III Controlled, Double-Blind, Randomized, Multinational Study for the Preventative Therapy of Latent Tuberculosis in HIV-positive Individuals: Isoniazid (300 mg/day x 12 months ) vs. Rifabutin (300 mg/day x 3 months)
Learn MoreCompleted
A Randomized Trial of the Use of N-acetylcysteine for the Prevention of Sulphonamide Hypersensitivity Reactions When Used for the Prevention of Pneumocystis Carinii Pneumonia in Patients with HIV infection: Trial results
Learn MoreCompleted
Evaluation of SQ32,756 (BV ara U) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV Infected Patients
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
